ZYNE — Zynerba Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeSmall Cap
- $70.12m
- $34.15m
Annual income statement for Zynerba Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.086 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 40.5 | 34.3 | 52.1 | 36.8 | 35.3 |
| Operating Profit | -40.4 | -34.3 | -52.1 | -36.8 | -35.3 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -39.9 | -32.9 | -51.3 | -37.3 | -35 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -39.9 | -32.9 | -51.3 | -37.3 | -35 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -39.9 | -32.9 | -51.3 | -37.3 | -35 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -39.9 | -32.9 | -51.3 | -37.3 | -35 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.61 | -1.5 | -1.9 | -0.95 | -0.821 |